ORCID Profile
0000-0002-4053-3915
Current Organisation
KU Leuven
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 23-03-2008
DOI: 10.1007/S11096-008-9211-X
Abstract: To compare and contrast the extent to which pharmacy students in Australia, Belgium, Finland, India, Estonia and Latvia hold stigmatising attitudes toward people with schizophrenia and severe depression. Data were collected as part of the International Pharmacy Students Health Survey, a census survey of third-year pharmacy students studying at eight universities in six countries. Respondents (n = 642) indicated how strongly they endorsed six stigmatising statements about patients with schizophrenia and severe depression. Coded data were analysed using the Statistical Package for the Social Sciences (Version 14.0). Between 52.5% (95% CI 46.2-58.9%) of students in Australia and 65.1% (95% CI 56.9-73.3) in Finland agreed that people with schizophrenia are a danger to others. Between 30.3% (95% CI 24.5-36.1%) of students in Australia and 60.0% (95% CI 48.5-71.5) in Estonia and Latvia agreed that people with schizophrenia are difficult to talk to. Between 9.8% (95% CI 4.0-15.6%) of students in Belgium and 43.8% (95% CI 35.3-52.3%) in Finland agreed that people with severe depression have themselves to blame. Sub-optimal attitudes toward people with schizophrenia and severe depression were common among pharmacy students in all countries. New models of pharmacy education are required to address the attitudes and misconceptions among pharmacy students.
Publisher: Mary Ann Liebert Inc
Date: 04-2010
Abstract: The aim of this study was to analyze changes in the prevalence and incidence of antidepressant use among children and adolescents in Finland post October, 2003. The s le comprised all children and adolescents in Finland aged < or =19.0 years (n = 27,676) who collected one or more reimbursed prescriptions for an antidepressant in noninstitutional and nonhospital settings between January, 1998, and December, 2005. Time-series models were used to compare antidepressant use 60 months before and 24 months after the health advisory issued by the Food and Drug Administration (FDA) in October, 2003. The annual prevalence (users/1,000 youths) of antidepressant use increased from 5.24 in 2002 to 5.93 in 2005. There was an increase in the monthly incidence (users = 1,000 youths) of selective serotonin reuptake inhibitors (SSRIs) use (+0.02498), fluoxetine use (+0.00691), and sertraline use (+0.00727) post October, 2003. When considering preadvisory trends in antidepressant use, only fluoxetine use was higher than the predicted post October 2003, use (<0.001). The use of all other SSRIs was significantly lower than predicted. In contrast to many other countries, the use of antidepressants continued to increase among children and adolescents in Finland post October, 2003. While the rate of fluoxetine use increased, there was a decline in the rate at which all other SSRIs were used.
Publisher: Elsevier BV
Date: 06-2019
DOI: 10.1016/J.SAPHARM.2018.09.002
Abstract: The Association of Pharmacists in Belgium (APB) and local pharmacy associations launched a pilot project in collaboration with research teams from three Belgian universities to study the impact and implementation-related issues of a medication review (MR) service type 2a in Belgian community pharmacies. The aim of this paper is to describe the implementation process of the MR service and to present the implementation evaluation of the pilot study (testing stage). The pilot project was a prospective observational study using mixed methods. The implementation evaluation was based on the RE-AIM model and the framework for the implementation of services in pharmacy (FISpH). Collected implementation outcomes were classified into four dimensions: reach, adoption, implementation and intent of maintenance. During the testing stage, 80 pharmacies participated in the study, but 25 dropped out (31%), mainly because of a reported lack of time (adoption). The 55 remaining pharmacies included 457 patients. Recruiting patients into the service was challenging for pharmacists as 48.5% of patients refused the pharmacists' proposal (reach). Internal organizational factors were major barriers for pharmacists, followed by the lack of adoption by the pharmacy team. Large pharmacies in which pharmacy owner led the project were observed to be more proactive in implementing the MR service by integrating organizational strategies to assist the implementation process (implementation). Interviewed pharmacists perceived this new service as a professionally satisfying activity. Among participating pharmacists, 92.5% found this service feasible in practice, but believed it required adapted resources to reorganize the internal pharmacy workload, additional support, such as broad-based media c aigns to increase physicians' and patients' awareness and attitudes towards the service, and modified software (maintenance). The medication review service was implemented in 68% of participating pilot Belgian community pharmacies but would require adapted resources and supports for larger scale implementation.
Publisher: Elsevier BV
Date: 02-2022
Publisher: Elsevier BV
Date: 10-2014
Publisher: SAGE Publications
Date: 27-10-2009
Abstract: Background: Healthcare professionals commonly exhibit negative attitudes toward people with mental disorders. Few international studies have sought to investigate the determinants of stigma. Objective: To conduct an international comparison of pharmacy students’ stigma towards people with schizophrenia, and to determine whether stigma is consistently associated with stereotypical attributes of people with schizophrenia. Method: Students ( n = 649) at eight universities in Australia, Belgium, India, Finland, Estonia and Latvia completed a seven-item Social Distance Scale (SDS) and six items related to stereotypical attributes of people with schizophrenia. Results: Mean SDS scores were 19.65 (± 3.97) in Australia, 19.61 (± 2.92) in Belgium, 18.75 (± 3.57) in India, 18.05 (± 3.12) in Finland, and 20.90 (± 4.04) in Estonia and Latvia. Unpredictability was most strongly associated with having a high social distance in Australia (β = —1.285), the perception that people will never recover in India (β = — 0.881), dangerousness in Finland (β = —1.473) and the perception of being difficult to talk to in Estonia and Latvia (β = —2.076). Unpredictability was associated with lower social distance in Belgium (β = 0.839). Conclusion: The extent to which students held stigmatizing attitudes was similar in each country, however, the determinants of stigma were different. Pharmacy education may need to be tailored to address the determinants of stigma in each country.
No related grants have been discovered for Veerle Foulon.